NCT06229548View on ClinicalTrials.gov

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 8, 2024

Primary Completion Date

December 23, 2024

Study Completion Date

March 25, 2025

Conditions

Hyperlipemia

Interventions

DRUG

SYH2053

subcutaneous injection

DRUG

Placebo

subcutaneous injection

Trial Locations (1)

Unknown

10 Chedaogou Rd.,Haidian District, Beijing, China, Beijing

All Listed Sponsors

lead

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

INDUSTRY

NCT06229548 - A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SYH2053 | Biotech Hunter | Biotech Hunter